CompBrief BY VELARION

Companies Alaunos Therapeutics, Inc.

Alaunos Therapeutics CEO salary & total pay, FY2025: $668K

Alaunos Therapeutics (TCRT) CEO salary, fiscal 2025: Holger Weis was paid a salary of $103,566 and $667,766 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Alaunos Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Holger Weis's complete compensation dossier

A PDF and a CSV sent to your email: Holger Weis's pay in every fiscal year Alaunos Therapeutics, Inc. reported it, line by line, with Holger Weis's equity grants and Alaunos Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$667,766CEO Holger Weis · source
Say-on-pay support61.03%Latest vote · source

CEO pay, last three years

  • $1,986,946FY2023
  • $392,500FY2024
  • $667,766FY2025

CEO total pay was $667,766 in fiscal 2025 (Holger Weis), up from $392,500 in fiscal 2024 (Kevin Boyle, the CEO that year).

FY2025: salary $103,566 · bonus $0 · stock awards $0 · option awards $564,200

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Alaunos Therapeutics, Inc. in fiscal 2025?
As disclosed, Holger Weis (Chief Executive Officer since July 2025) was the highest-paid executive at Alaunos Therapeutics, Inc. in fiscal 2025, with total compensation of $667,766.
How did shareholders vote on Alaunos Therapeutics, Inc.'s executive compensation?
As disclosed, 61.03% of shareholders supported Alaunos Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Alaunos Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Alaunos Therapeutics, Inc. reported total board compensation of $194,896 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Holger Weis$103,566$0$0$564,200$0$0$0$667,766
Chief Executive Officer since July 2025
Melinda Lackey0003,08700249,335250,604
Former Legal & Administration, Corporate Secretary
Ferdinand Groenewald0025,00011,98800180,000216,988
Vice President, Finance
Dale Hogue139,744003,748000143,492
Former Interim Chief Executive Officer as of July 2025

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Holger Weis$667,766———
Melinda Lackey250,604430,370831,737↓ −179,766
Ferdinand Groenewald216,988162,304—↑ +54,684
Dale Hogue143,492308,34448,153↓ −164,852

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The company believes long-term equity incentive compensation is a critical component of its executive compensation program that links the interests of executive officers with those of stockholders. Stock options are used to align executives' realizable compensation with the creation of stockholder value and serve as an effective long-term incentive vehicle to retain talent and incentivize performance.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantPearl Meyer and Partners, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Holger WeisOPTION2025-07-02——130,000——

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Ferdinand GroenewaldOption4691,4062.42—
Ferdinand GroenewaldOption2,2507501.46—
Holger WeisOption40,62589,3755.02—
Holger WeisOption1,000—646.5—
Holger WeisOption208—646.5—
Holger WeisOption666—123—
Holger WeisOption666—72—
Holger WeisOption452—10.3—
Holger WeisOption1,920—10.3—
Holger WeisOption10,904—2.92—
Holger WeisOption13,676—2.32—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jaime VieserIndependent · Audit · Compensation · Corporate Governance and Nominating$0$84,875$0——$84,875
Robert W. PostmaIndependent · Audit · Compensation · Corporate Governance and Nominating079,0500——79,050
Michael A. JermanIndependent · Audit · Compensation · Partial-year service · Newly elected013,22138,744——51,965
Holger WeisEmployee director0048,478——48,478
Robert J. Hofmeister, Ph.DIndependent · Partial-year service17,75000——17,750

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$17,750
Equity awards (grant-date value)$177,146
All other compensation$0
Total cost of the board$194,896

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Alaunos Therapeutics as a peer

Companies that benchmark against TCRT

No companies currently name TCRT as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Alaunos Therapeutics, Inc.2025Holger Weis$103,566$0$564,200$0$667,766

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-07-03232,638144,9573,56661.03%Passed
20242024-06-061,851,8461,032,78985,11162.36%Passed
20232023-06-0685,893,57220,980,8481,948,70078.93%Passed
20222022-06-1388,627,0657,777,8745,651,31986.84%Passed
20212021-05-1998,887,1736,555,935464,67793.37%Passed
20202020-06-2976,263,36858,155,2261,097,41456.28%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20252025-07-0361.03%a
20242024-06-0662.36%b
20232023-06-0678.93%c

a. Approved under the standard stated in the filing — “Approval, on an advisory basis, of the compensation of our named executive officers -- The affirmative vote of a majority in voting power of shares of stock present in person or represented by proxy and entitled to vote thereon. | Abstentions: Against”.

b. Approved under the standard stated in the filing — “Approval, on an advisory basis, of the compensation of our named executive officers -- "For" votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter. | Abstentions: Against”.

c. Approved under the standard stated in the filing — “Abstentions will have the same effect as “Against” votes on Proposal 2, Proposal 3, the Reverse Stock Split Proposal, the Authorized Stock Increase Proposal and the Adjournment Proposal, and will have no effect on Proposals 1 and 4.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Holger WeisChief Executive Officer2026-05-22A3,700$2$8,769CommonForm 4 ↗
Holger WeisChief Executive Officer2026-06-12A7,761217,540CommonForm 4 ↗
Holger WeisChief Executive Officer2026-06-30A3,88028,769CommonForm 4 ↗
Jaime VieserDirector2026-07-23A8,789216,875CommonForm 4 ↗
Robert W. PostmaDirector2026-07-23A8,463216,249CommonForm 4 ↗
Michael A. JermanDirector2026-07-23A8,138215,625CommonForm 4 ↗
Holger WeisCEO2026-07-23A4,56828,771CommonForm 4 ↗
Holger WeisCEO2026-08-06A4,36328,770CommonForm 4 ↗
Holger WeisCEO2026-10-06A23,564117,541CommonForm 4 ↗
Robert W. PostmaDirector2026-10-06A21,829116,250CommonForm 4 ↗
Jaime VieserDirector2026-10-06A22,669116,875CommonForm 4 ↗
Michael A. JermanDirector2026-10-06A20,990115,625CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (28 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Holger Weis. 10-K/A, filed 2026-04-30. Section “Executive Compensation” · page 10. As printed: 667,766. View filing ↗
  • Section 01, Melinda Lackey. 10-K/A, filed 2026-04-30. Section “Executive Compensation” · page 10. As printed: 250,604. View filing ↗
  • Section 01, Ferdinand Groenewald. 10-K/A, filed 2026-04-30. Section “Executive Compensation” · page 10. As printed: 216,988. View filing ↗
  • Section 01, Dale Hogue. 10-K/A, filed 2026-04-30. Section “Executive Compensation” · page 10. As printed: 143,492. View filing ↗
  • Section 03, Holger Weis OPTION. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 08, Jaime Vieser. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 84,875. View filing ↗
  • Section 08, Robert W. Postma. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 79,050. View filing ↗
  • Section 08, Michael A. Jerman. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 51,965. View filing ↗
  • Section 08, Holger Weis. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 48,478. View filing ↗
  • Section 08, Robert J. Hofmeister, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 17,750. View filing ↗
  • Section 02, Holger Weis 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Holger Weis 2026-06-12. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Holger Weis 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jaime Vieser 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert W. Postma 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael A. Jerman 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Holger Weis 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Holger Weis 2026-08-06. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Holger Weis 2026-10-06. Form 4, filed 2026-10-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert W. Postma 2026-10-06. Form 4, filed 2026-10-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jaime Vieser 2026-10-06. Form 4, filed 2026-10-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael A. Jerman 2026-10-06. Form 4, filed 2026-10-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-07-10. Item 5.07 · say-on-pay result. As reported: 61.03% (votes for as printed: 232,638). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 62.36% (votes for as printed: 1,851,846). View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-12. Item 5.07 · say-on-pay result. As reported: 78.93% (votes for as printed: 85,893,572). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 17,750 + equity 177,146 + all other 0 = 194,896, summed across the director compensation table rows.
  • Alaunos Therapeutics, Inc. (subject), Section 10b CEO total. 10-K/A, filed 2026-04-30. CEO total compensation as printed in Alaunos Therapeutics, Inc.'s own proxy. As printed: 667,766. View filing ↗
Get the full report — $299